Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the upcoming Piper Sandler 38th Annual Healthcare Conference.
Stocks · News reference
Filed: 2026-11-09 AccNo: 0001104659-26-124502 Size: 587 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Orchestra BioMed Holdings, Inc. announced its participation in the upcoming Piper Sandler 38th Annual Healthcare Conference.
An analyst has increased the price target for Orchestra BioMed Holdings, Inc. to $12.00 per share.
Orchestra BioMed announced its third-quarter 2026 financial results, highlighted the completion of enrollment for its BACKBEAT pivotal trial, and confirmed a cash runway extending through 2028.
Orchestra BioMed Holdings, Inc. has priced an underwritten public offering of 15 million shares of its common stock at $5.00 per share.
Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 15 million shares at $5.00 per share, expected to raise $75 million in gross proceeds. The company plans to use the funds to advance its AVIM Therapy program and BACKBEAT clinical trial for hypertension treatment, as well as its Virtue SAB program for coronary in-stent restenosis, alongside other research and development initiatives.